Further assessment is needed to understand if these treatment recommendations were eventually adopted and if adoption leads to better outcomes,” researchers wrote.

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

The FDA has approved the biologics license applications for Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, respectively.

Although there was a significant decline in the age-adjusted incidence-based mortality rate from 2006 to 2020, our study did not show a significant improvement in survival outcomes,” the researchers ...

Consuming a lower-fat diet and taking a fish oil supplement daily reduced the Ki-67 index in patients with prostate cancer on active surveillance.

Data suggest that adding an ARPI to standard care improves outcomes for most patients with mHSPC, but those benefits decrease with age.

(HealthDay News) — Overdiagnosis of thyroid cancer remains a persistent problem in the United States, researchers reported in The Lancet Diabetes & Endocrinology.

Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

First-line cemiplimab and platinum-based chemotherapy appears to be safe and effective for patients with advanced penile carcinoma.